Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
43 studies found for:    cholangiocarcinoma AND duct adenocarcinoma | Open Studies
Show Display Options
Rank Status Study
1 Not yet recruiting Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma
Conditions: Non-Resectable Cholangiocarcinoma;   Recurrent Cholangiocarcinoma;   Stage III Extrahepatic Bile Duct Cancer;   Stage III Intrahepatic Cholangiocarcinoma;   Stage IIIA Hilar Cholangiocarcinoma;   Stage IIIB Hilar Cholangiocarcinoma;   Stage IVA Extrahepatic Bile Duct Cancer;   Stage IVA Hilar Cholangiocarcinoma;   Stage IVA Intrahepatic Cholangiocarcinoma;   Stage IVB Extrahepatic Bile Duct Cancer;   Stage IVB Hilar Cholangiocarcinoma;   Stage IVB Intrahepatic Cholangiocarcinoma;   Unresectable Extrahepatic Bile Duct Carcinoma
Interventions: Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Ricolinostat
2 Recruiting Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Conditions: Acinar Cell Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Appendix Mucinous Adenocarcinoma;   Bladder Adenocarcinoma;   Bronchioloalveolar Carcinoma;   Cervical Adenocarcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Dermoid Cyst;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Fallopian Tube Adenocarcinoma;   Fibromyxoid Tumor;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metastatic Malignant Neoplasm of Unknown Primary Origin;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Placental-Site Gestational Trophoblastic Tumor;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Malignant Transformation;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Undifferentiated Gastric Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Adenocarcinoma;   Vulvar Squamous Cell Carcinoma
Interventions: Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
3 Recruiting RFA RCT for Pancreatic or Bile Duct Cancer
Conditions: Unresectable Pancreatic Cancer;   Cholangiocarcinoma Non-resectable
Interventions: Procedure: Radiofrequency Ablation using EndoHPB Probe;   Procedure: Stenting only
4 Recruiting A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
Condition: Metastatic Biliary Tract Carcinoma
Intervention: Drug: Regorafenib
5 Not yet recruiting A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma
Condition: Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: gemcitabine;   Drug: Cisplatin;   Drug: Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C
6 Not yet recruiting Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer
Conditions: Adenocarcinoma Metastatic;   Biliary Tract Cancer;   Adenocarcinoma of the Biliary Tract;   Adenocarinoma Locally Advanced;   Non-Resectable Hepatocellular Carcinoma;   Intrahepatic Bile Duct Carcinoma;   Extrahepatic Bile Duct Carcinoma
Interventions: Drug: Arm NaI-IRI + 5-FU + Leucovorin (Arm A);   Drug: Arm Cisplatin + Gemcitabine (Arm B)
7 Recruiting Treatment for Bile Duct Cancer in the Liver
Condition: Cholangio Carcinoma
Intervention: Drug: SIRT Yttrium-90
8 Recruiting Lipidomics, Proteomics, Micro RNAs and Volatile Organic Compounds
Condition: Pancreatic Neoplasms
Intervention: Other: blood and bile
9 Recruiting Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma
Condition: Malignant Neoplasm Other Gallbladder/Extrahepatic Bile Duct
Interventions: Radiation: Concurrent Chemoradiotherapy;   Drug: capecitabine;   Drug: gemcitabine
10 Recruiting Endoscopic Biliary RFA of Malignant Bile Duct Obstruction
Conditions: Cholangiocarcinoma;   Bile Duct Obstruction
Interventions: Procedure: SEMS alone;   Procedure: SEMS plus radiofrequency ablation
11 Recruiting Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma
Conditions: Cholangiocarcinoma;   Biliary Stricture;   Biliary Obstruction;   Bile Duct Cancer
Intervention: Procedure: Photodynamic Therapy
12 Recruiting Endoscopic Biliary Radiofrequency Ablation of Malignant Distal Common Bile Duct Strictures
Conditions: Pancreatic Cancer;   Cholangiocarcinoma
Interventions: Procedure: SEMS only;   Procedure: EBRFA and SEMS
13 Not yet recruiting Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma
Conditions: Bile Duct Cancer;   Intrahepatic Cholangiocarcinoma
Interventions: Combination Product: Melphalan/HDS;   Drug: Cisplatin and Gemcitabine
14 Recruiting Trial of Therapeutic Vaccine in Patients With Cholangiocarcinoma
Condition: Cholangiocarcinoma
Intervention: Biological: Oral therapeutic vaccine V3-X to treat cholangiocarcinoma
15 Recruiting Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers
Conditions: Cholangiocarcinoma;   Tumor;   Klatskin Tumor
Intervention: Drug: Temoporfin
16 Recruiting CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
Conditions: Adult Primary Cholangiocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Cholangiocarcinoma of the Extrahepatic Bile Duct;   Cholangiocarcinoma of the Gallbladder;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Extrahepatic Bile Duct Cancer;   Recurrent Adult Primary Liver Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Unresectable Extrahepatic Bile Duct Cancer
Intervention: Drug: 6,8-bis(benzylthio)octanoic acid
17 Recruiting Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Adenocarcinoma of the Gallbladder;   Adenocarcinoma of Unknown Primary;   Adult Primary Cholangiocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Cholangiocarcinoma of the Extrahepatic Bile Duct;   Cholangiocarcinoma of the Gallbladder;   Diffuse Adenocarcinoma of the Stomach;   Duct Cell Adenocarcinoma of the Pancreas;   Intestinal Adenocarcinoma of the Stomach;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Carcinoma of Unknown Primary;   Metastatic Extrahepatic Bile Duct Cancer;   Mixed Adenocarcinoma of the Stomach;   Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Newly Diagnosed Carcinoma of Unknown Primary;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage III Pancreatic Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Gallbladder Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Gallbladder Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Rectal Cancer;   Stage IV Gastric Cancer;   Stage IV Pancreatic Cancer;   Stage IVA Colon Cancer;   Stage IVA Gallbladder Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Gallbladder Cancer;   Stage IVB Rectal Cancer;   Unresectable Extrahepatic Bile Duct Cancer
Interventions: Drug: oxaliplatin;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: fluorouracil;   Other: laboratory biomarker analysis
18 Recruiting Percutaneous Bilateral Versus Unilateral Metal Stent for Hilar Cholangiocarcinoma
Condition: Hilar Cholangiocarcinoma
Interventions: Procedure: bilateral metal stent insertion;   Procedure: unilateral metal stent insertion
19 Recruiting Diagnosis of Bile Duct Strictures
Conditions: Bile Duct Stricture;   Cholangiocarcinoma;   Pancreatic Cancer;   Chronic Pancreatitis
Intervention: Other: brushing of bile duct strictures for cytology
20 Recruiting Liver Resection Versus Radio-chemotherapy-Transplantation for Hilar Cholangiocarcinoma
Conditions: Cholangiocarcinoma;   Morphological Diagnosis of Hilar Cholangiocarcinoma (Excluded Type 1), Resectable With Expected R0 Margins on an intent-to Treat Basis.
Interventions: Procedure: CAPECITABINE-Radiotherapy -Liver Transplantation;   Procedure: RESECTION

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.